Image

Blood Biomarkers to Improve Management of Children With Traumatic Brain Injury

Recruiting
- 18 years of age
Both
Phase N/A

Powered by AI

Overview

Mild traumatic brain injury (TBI), defined by a Glasgow Coma Scale (GCS) score of 13 to 15, is the cause of many consultations in paediatric emergency departments (1), even though it is a rare cause of acute complication: approximately 10% of children present with intracranial lesions (ICL) on the CT scan and less than 1% require neurosurgical intervention (2). Although ICLs remain a serious complication requiring rapid diagnosis, brain CT scans, the gold standard diagnostic test, cannot be performed routinely because many children would be unnecessarily exposed to ionising radiation associated with an increased risk of cancer (3). In recent years, several clinical decision rules for the management of mTBI have therefore been developed with the aim of identifying children at high or very low risk of ICL in order to better target CT scan indications. Despite this, the rate of CT scans performed has remained high, up to 35%, and has not decreased with the application of these clinical decision rules (4).

Furthermore, even though the majority of children and adolescents recover quickly after mTBI, nearly 30% will present symptoms such as headaches, dizziness, asthenia, memory, concentration or sleep disorders persisting beyond one month with a possible impact on their quality of life (5). Thus, there is a need to develop new strategies to (i) limit the use of CT scans while minimising the risk of late diagnosis of ICL, (ii) identify children with a higher risk of adverse outcome and/or post-concussive symptoms.

One of the most promising strategies is the use of brain-based blood biomarkers. This study therefore aims to provide new knowledge on two of them, GFAP and UCH-L1 (6,7), in particular by using an automated test combining them (the VIDAS® TBI test developed by bioMérieux) in order to improve the management of CT in the paediatric population at the diagnostic and prognostic levels.

Eligibility

Inclusion Criteria:

        Children and adolescents <18 years old Consent from one of the parents of the child or from
        holder of parental responsibility Consent from the child or adolescent Parental affiliation
        with an appropriate health insurance system
          1. TBI population
               -  Admission within 24 hours of the injury
               -  Ability to follow-up by telephone, mail or email
               -  For the mTBI group:
                    -  GCS score of 13-15 on admission
                    -  Indication for cerebral CT scan according to national or local guidelines or
                       the in-charge physician OR diagnosis of concussion consistent with the
                       fourth Zurich consensus statement (9) . Concussion was defined as a complex
                       pathophysiological process caused by a direct blow to the head, face, neck,
                       or elsewhere on the body with an impulsive force transmitted to the head
                       (which may or may not have involved loss of consciousness), resulting in a
                       brain injury with one or more symptoms in one or more of the following
                       clinical domains: somatic, cognitive, emotional or behavioural, or sleep. To
                       objectively help diagnose concussion, the validated Acute Concussion
                       Evaluation (ACE) questionnaire (10) for children with mTBI will be used, the
                       presence of ≥ 1 symptom on the ACE defines concussion.
               -  For the moderate or severe TBI group:
                    -  GCS score of 3-12 on admission
                    -  Indication for cerebral CT scan according to national or local guidelines or
                       the in-charge physician
          2. Non-TBI control paediatric population
               -  Admission for any reason other than TBI
               -  Indication of blood sampling for their routine management
               -  GCS score of 15
               -  Otherwise healthy, i.e. without chronic pathology
        Exclusion Criteria:
          1. TBI population
               -  Time of injury unknown or exceeding 24 hours
               -  Blood sampling not possible within 24 hours after the injury or 6 hours after the
                  CT scan, if applicable
               -  Penetrating brain injury with skull fracture
               -  Pre-existing neurological disorders affecting the assessment of neurological
                  outcome, seizure disorder/epilepsy, brain tumour, history of neurosurgery,
                  stroke, encephalopathy
               -  Venepuncture not feasible
               -  Pregnant woman
               -  Intoxication
               -  No clear primary mechanism of trauma
               -  No possibility for transferring CT scan images to the centralised platform in
                  case of neuroimaging only performed in an outside hospital before transfer
               -  Participation in another interventional research study
          2. Non-TBI control paediatric population
               -  Pre-existing neurological disorders, seizure disorder/epilepsy, brain tumour,
                  history or indication of neurosurgery, stroke, encephalopathy
               -  History of TBI
               -  Orthopaedic trauma or surgery within the last month
               -  Suspected meningitidis or encephalitis
               -  Venepuncture not feasible
               -  Pregnant woman
               -  Intoxication
               -  Participation in another interventional research study

Study details

Traumatic Brain Injury

NCT05413499

Nantes University Hospital

26 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.